Daily treatment with diazoxide choline controlled release (DCCR) leads to sustained reductions in excessive appetite and other symptoms of Prader-Willi syndrome (PWS), according to updated findings from a Phase 3 trial. “The results from this program continue to demonstrate DCCR’s beneficial impact on hyperphagia [excessive appetite], the…
News
An online survey from Trinity College Dublin is seeking input from the parents and caregivers of young people with Prader-Willi syndrome about the impact of the COVID-19 pandemic on the children’s mental health and behavior. Besides Prader-Willi, the scientists are also studying patients with autism, as well…
It took one year for Dona Krystosek to get a diagnosis for her son, Levi, after he was born. The family received three misdiagnoses of fatal diseases until they found out Levi has Jansen’s metaphyseal chondrodysplasia — an extremely rare form of dwarfism. “The hardest…
Levels of uric acid in the blood are lower in adults with Prader-Willi syndrome (PWS) who are obese than in people without PWS but who also are obese, a study shows. Fat-free body mass was the strongest predictor of uric acid levels. Researchers…
Text messages may help to track changes in the weight and body mass index (BMI) of people with Prader-Willi syndrome (PWS), an observational study reported. Most study patients were “highly compliant” with using this mobile technology, and it might help in clinical trials of potential treatments or with…
Japanese infants with Prader-Willi syndrome (PWS) have lower levels of the thyroid hormone thyroxine compared with healthy infants, according to a new study. However, the levels of thyroxine, also known as free T4 (FT4), increased with age, with no differences detected between toddlers with or without PWS,…
Lallemand Health Solutions has partnered with the Prader-Willi Syndrome Association (PWSA) to support Running for Research, an initiative to raise funds for PWS research at the University of Florida (UF). Running for Research has set a fundraising goal of at least $40,000, and will take place…
Inversago Pharma has obtained $35 million in financing to advance the development of therapies for disorders such as Prader-Willi syndrome (PWS). The investment will support studies of INV-101, the company’s lead compound, and other selected compounds for the treatment of metabolic and fibrotic (scarring) disorders. INV-101 is an…
Researchers in Russia have published the first detailed description of a prenatal Prader-Willi syndrome (PWS) diagnosis based on the results of a noninvasive genetic test. The study, “Prenatal diagnosis of Prader‐Willi syndrome due to uniparental disomy with NIPS: Case report and literature review,” was published in…
An exercise intervention program can improve bone health in children with Prader-Willi syndrome (PWS) and potentially lower the risk of osteoporosis later in life, a six-month clinical trial shows. While improvements were reported in only some bones, and not in markers of bone turnover, researchers believe that longer intervention…
Recent Posts
- Study IDs genetic subtype as possible psychosis risk factor in PWS
- We’re running our own race without the milestone charts, one win at a time
- Oxygen therapy brings sweet comfort to infants with PWS sleep apnea
- Why we said yes to adopting 2 children with Prader-Willi syndrome
- Study links age, genetic cause to quality of life in Prader-Willi syndrome
- Understanding the causes of anxiety in PWS helps to process the questions
- Vykat XR safely quiets the intense Prader-Willi hunger for years
- First participant dosed in Phase 2a trial of CSTI-500 for Prader-Willi syndrome
- Setmelanotide successfully targeting extreme hunger, obesity in PWS trial
- PWS study disputes growth hormone link to infant sleep apnea